Brief reportPublished 30 Nov 2024
Evaluation of the Cost-effectiveness and Cost-utility of Palbociclib Compared to Ribociclib in Women with Stage IV Breast Cancer: An Analysis Using Real-world Data
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The evaluation of the cost-effectiveness and cost-utility of Palbociclib and Ribociclib in the treatment of women with stage IV breast cancer, using real-world data, is crucial in understanding the value these treatments provide within a clinical and economic context. Stage IV breast cancer, also known as metastatic breast cancer, presents one of the most significant challenges in oncology due to its advanced progression and the complexity of treatment options. In recent years, targeted therapies such as Palbociclib and Ribociclib, both of which are cycling-dependent kinase inhibitors, have been introduced as promising options for treating HR-positive, HER2-negative metastatic breast cancer. These therapies, however, come with high costs, raising questions about their value in terms of both clinical outcomes and economic implications
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmacoeconomics: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Cost-effectiveness”
- BylineArticles whose byline prints “Cost-utility”
- BylineArticles whose byline prints “Ribociclib”
